Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
09/09/2026
UCB received US FDA BTD for CIMZIA in pregnant women with antiphospholipid syndrome.
Beeline Medicines announced topline results from the Phase 2 study of afimetoran in SLE.
UCB received US FDA BTD for CIMZIA in pregnant women with antiphospholipid syndrome. (Ref)
UCB announced that the US FDA had granted Breakthrough Therapy Designation (BTD) to CIMZIA® (certolizumab pegol) for the prevention of placenta-mediated adverse pregnancy outcomes in addition to standard anti-coagulant therapy, in at-risk pregnant adult women who have antiphospholipid syndrome (APS) and are positive for lupus anticoagulant (LA).
The BTD was supported by findings from the investigator-initiated IMPACT study, which demonstrated the potential of CIMZIA® to address a significant unmet need for women with APS.
Beeline Medicines announced topline results from the Phase 2 study of afimetoran in SLE. (Ref)
Beeline Medicines announced positive topline results from the Phase 2/ NCT04895696 study of afimetoran (TLR7 and TLR8 inhibitor) in systemic lupus erythematosus (SLE).
The study met its primary endpoint, with with all three afimetoran dose groups demonstrating higher SRI-4 response rates vs placebo at Week 48 (p-value <0.001 across all dose groups).
Secondary endpoints demonstrated improvements consistent with the primary endpoint findings.
The safety and tolerability of afimetoran were generally consistent with previous Phase 1 clinical trial experience, and no new safety signals were observed.
Afimetoran previously demonstrated exploratory efficacy in a Phase 1b study in cutaneous lupus erythematosus and was granted Fast Track designation by the US FDA for SLE in May 2025.
The Company planned to advance afimetoran into pivotal development for both SLE and CLE.


